Clinical trials · Riverside–San Bernardino, CA
Carcinoma clinical trials in Riverside–San Bernardino
We’re tracking 340 recruiting carcinoma studies with a site in or near Riverside–San Bernardino — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT07186699Recruiting
Understanding lung cancer in people with past alcohol or drug use
This study looks at the experiences of people with lung cancer (NSCLC) who also have a history of alcohol or drug use. It aims to help doctors better understand and support patients facing both challenges.
Los Angeles, CaliforniaAges 18 years+ - NCT06992427RecruitingPhase 3
Gabapentin to prevent opioid use for mouth pain during cancer treatment
This trial tests if taking gabapentin during chemoradiation for head and neck cancer can reduce the need for strong painkillers like opioids. It may help manage mouth pain caused by treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06882746RecruitingPhase 1
Testing different doses of BI 765049 for advanced colorectal, stomach, or pancreatic cancer
This study tests a new drug (BI 765049) at different doses for people with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe and effective dose.
Los Angeles, CaliforniaAges 18 years+ - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Los Angeles, CaliforniaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT04703101RecruitingPhase 1
Short radiation plus chemo for stage II–III rectal cancer
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05978128Recruiting
Use advocates to boost lung cancer screening
This trial tests whether trained advocates and supporters can help people who are eligible for lung cancer screening actually get screened. It may help you (and others) by making screening easier to plan and complete.
Los Angeles, CaliforniaAges 40–80 - NCT07185165RecruitingPhase 2
PET Scan for Prostate Cancer Recurrence After Focal Therapy
This study uses a special PET/CT scan (Flotufolastat F 18) to look for leftover or returning prostate cancer after you've had a targeted treatment called focal therapy. The goal is to see if the scan can help find cancer that might need further treatment.
Los Angeles, CaliforniaAges 18–90 - NCT04857502RecruitingEarly Phase 1
Tracking prostate cancer spread before lymph node surgery
This early study uses a special imaging tracer to show where prostate cancer has spread in the pelvic lymph nodes. It may help doctors better understand how well certain scans guide surgical removal of affected lymph nodes.
Los Angeles, CaliforniaAges Any age - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Los Angeles, CaliforniaAges 18 years+ - NCT05751434RecruitingPhase 2
Exercise therapy for prostate cancer patients on active surveillance
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
Los Angeles, CaliforniaAges 18 years+ - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Los Angeles, CaliforniaAges 18 years+ - NCT06568016Recruiting
Helping patients get colonoscopy after abnormal stool test
This study tests a new clinic program to help patients complete a colonoscopy if they received an abnormal result from a fecal immunochemical test (FIT), a simple stool test for colon cancer. It focuses on community health centers and aims to make follow-up care easier.
Los Angeles, CaliforniaAges Any age - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Carcinoma trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Carcinoma trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting carcinoma studies listed above.
- UCLA / Jonsson Comprehensive Cancer Center · 7 studies
- USC / Norris Comprehensive Cancer Center · 6 studies
- University of California, Los Angeles (UCLA) · 4 studies
- Los Angeles General Medical Center · 2 studies
- The Angeles Clinic and Research Institute · 2 studies
- Cedars-Sinai Medical Center
- Helios Clinical Research
- Los Angeles Cancer Network
What taking part in a carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting carcinoma studies in California.
Common questions
- Are there carcinoma clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 340 recruiting carcinoma studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a carcinoma study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New carcinoma studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.